Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon

SummaryThe conclusions of studies to date which evaluate a possible association between factor V Leiden and adverse pregnancy outcome have been conflicting. This study was undertaken to further investigate this association. Our objective was to evaluate the association between adverse pregnancy outcomes and maternal factor V Leiden genotype by meta-analysis. Inclusion criteria were: (a) cohort or case control design; (b) outcomes clearly defined as one of the following: first or second/ third trimester miscarriage or intrauterine death, preeclampsia, fetal growth retardation, or placental abruption; (c) both the case and control mothers tested for the factor V Leiden mutation; (d) sufficient data for calculation of an odds ratio. Both fixed and random effect models were used to pool results and heterogeneity and publication bias were checked. For first trimester fetal loss, the pooled odds ratio was heterogeneous (p=0.06) and no dose-response curve could be found. For second/third trimester fetal loss, there was a consistent and graded increase in risk: the odds ratio was 2.4 (95% CI 1.1-5.2) for isolated (non-recurrent) third trimester fetal loss, rising to 10.7 (95% CI 4.0-28.5) for those with 2 or more second/third trimester fetal losses. FactorV Leiden is associated with a 2.9 fold (95% CI 2.0-4.3) increased risk of severe preeclampsia, and a 4.8 fold (95% CI 2.4-9.4) increased risk of fetal growth retardation. These results support factor V Leiden testing for women with recurrent fetal loss in the second/third trimester. Women with only 1 event may also warrant testing if the fetal loss occurred in the third trimester. Conversely, in those women known to have the factor V Leiden mutation, monitoring for adverse pregnancy outcomes is warranted; whether this means increased vigilance or anti-coagulant prophylaxis is still contentious.

Download Full-text

Prevalence of factor V-Leiden, prothrombin and methylene tetrahydrofolate reductase gene mutations in women with adverse pregnancy outcome

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2005.10.573 ◽

2005 ◽

Vol 193 (6) ◽

pp. S86

Author(s):

Rony Rayyes ◽

Laila Zahed ◽

Rami Mahfouz ◽

Ali Taher ◽

Anwar Nassar

Keyword(s):

Pregnancy Outcome ◽

Adverse Pregnancy Outcome ◽

Gene Mutations ◽

Factor V Leiden ◽

Factor V ◽

Methylene Tetrahydrofolate Reductase ◽

Reductase Gene ◽

Methylene Tetrahydrofolate ◽

Adverse Pregnancy

Download Full-text

Addendum to: The association between adverse pregnancy outcomes and maternal factor V Leiden genotype. A meta-analysis

Thrombosis and Haemostasis ◽

10.1055/s-0037-1613736 ◽

2004 ◽

Vol 92 (08) ◽

pp. 434 ◽

Cited By ~ 2

Author(s):

John Attia ◽

Claire Infante-Rivard ◽

Tracy Dudding

Keyword(s):

Pregnancy Outcomes ◽

Meta Analysis ◽

Factor V Leiden ◽

Adverse Pregnancy Outcomes ◽

Factor V ◽

Maternal Factor ◽

Adverse Pregnancy ◽

Genotype A

Download Full-text

Factor V Leiden Mutation and its Impact on Pregnancy Complications

Acta Medica (Hradec Kralove Czech Republic) ◽

10.14712/18059694.2016.32 ◽

2011 ◽

Vol 54 (3) ◽

pp. 117-121 ◽

Cited By ~ 1

Author(s):

Ľubica Hammerová ◽

Ján Chabada ◽

Juraj Drobný ◽

Angelika Bátorová

Keyword(s):

Venous Thromboembolism ◽

Pregnancy Outcomes ◽

Factor V Leiden ◽

Adverse Pregnancy Outcomes ◽

Intrauterine Fetal Death ◽

Control Group ◽

Factor V ◽

Factor V Leiden Mutation ◽

Significant Difference ◽

Adverse Pregnancy

Objective: The aim of this prospective study was to find the association between the factor V Leiden mutation and adverse pregnancy outcomes. Methods: This study is an analysis of a prospective observational study of the frequency of placenta-mediated complications of factor V Leiden mutation carriers. We compared pregnancy outcomes of 11 women with a heterozygous form of the factor V Leiden mutation with 41 women of a control group. Results: All pregnancies ended with delivery of a living infant. None of the 52 pregnancies were complicated by venous thromboembolism. There were a few significant differences regarding placenta-mediated complications. The gestational age at delivery showed small significant differences. There was a significant difference in the birth weight deviation in percentage between FVL carriers and controls. The incidence of blood loss exceeding 1000 ml was higher in the control group. Conclusions: Carriership of the factor V Leiden mutation did not affect the incidence of preeclampsia. Adverse pregnancy outcomes such as placental abruption were rare. Eclampsia, intrauterine fetal death and venous thromboembolism did not occur. Our results provide evidence that the maternal heterozygous FVL mutation did not increase the risk of an adverse pregnancy outcome.

Download Full-text

Potential role of Factor V Leiden mutation in adverse pregnancy outcomes: An updated systematic review

Biomedical Research and Therapy ◽

10.15419/bmrat.v4i12.389 ◽

2017 ◽

Vol 4 (12) ◽

pp. 1832 ◽

Cited By ~ 3

Author(s):

Nasibeh Roozbeh ◽

Farzaneh Banihashemi ◽

Mitra Mehraban ◽

Fatemeh Abdi

Keyword(s):

Systematic Review ◽

Pregnancy Outcomes ◽

Placental Abruption ◽

Factor V Leiden ◽

Adverse Pregnancy Outcomes ◽

Factor V ◽

Spontaneous Abortions ◽

Factor V Leiden Mutation ◽

Adverse Pregnancy ◽

Fvl Mutation

Background: Thrombophilia is an inherited or acquired predisposition for development of thrombosis. One of the common thrombophilia polymorphisms is Factor V Leiden (FVL) mutation, which may contribute to negative pregnancy outcomes. This systematic review study seeks to describe the potential effects of factor V Leiden mutation on adverse pregnancy outcomes. Methods: Pubmed, Embase, ISI Web of Sciences, Scopus, ScienceDirect, Proquest and Google Scholar, for articles published during 1996-2017. Articles were evaluated by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for standard reporting. As well, the quality of studies was assessed by the Newcastle-Ottawa Scale (NOS). Results: A total of 14 studies were eligible based on the inclusion criteria. The papers were scored by the STROBE checklist. The range of STROBE score was 15-20. Only 37.5% of the studies confirmed the relationship between fetal loss and FVL. The effect of FVL mutation on spontaneous abortions and In Vitro Fertilization (IVF) failures was demonstrated in all the studies. In the reviewed studies, there was no observed relationship between FVL mutation with intrauterine growth restriction (IUGR), preeclampsia, placental abruption or small for gestational age (SGA). Conclusion: The reviewed studies showed an unclear association between FVL mutation and stillbirth, IUGR, preeclampsia, or placental abruption. The exact effects of hereditary thrombophilia on pregnancy outcome is also still controversial. However, FVL mutation appeared to have an effect on spontaneous abortions and IVF failures. Therefore, screening patients for thrombophilic polymorphisms might be helpful.

Download Full-text

Factor V Leiden, C>T MTHFR Polymorphism and Genetic Susceptibility to Preeclampsia

Thrombosis and Haemostasis ◽

10.1055/s-0038-1656110 ◽

1997 ◽

Vol 77 (06) ◽

pp. 1052-1054 ◽

Cited By ~ 152

Author(s):

Elvira Grandone ◽

Maurizio Margaglione ◽

Donatella Colaizzo ◽

Giuseppe Cappucci ◽

Dario Paladini ◽

...

Keyword(s):

Genetic Susceptibility ◽

Factor V Leiden ◽

Controlled Study ◽

Control Group ◽

Gene Variants ◽

Factor V ◽

Mthfr Polymorphism ◽

Methylene Tetrahydrofolate Reductase ◽

Fv Leiden ◽

Methylene Tetrahydrofolate

SummaryWe performed a case-controlled study to investigate whether the FV Leiden mutation and the C>T677 polymorphism of the 5,10 methylene tetrahydrofolate reductase (MTHFR) are associated with the occurrence of preeclampsia in 96 otherwise healthy preeclamptic women and 129 parous women as controls. FV Leiden carriers were 10 (10.5%) in cases and 3 (2.3%) in controls (OR: 4.9, 95% Cl: 1.3-18.3). MTHFR TT homozygotes were 28 (29.8%) in cases and 24 (18.6%) in the control group (OR: 1.8,95% Cl 1.0-3.5). No difference in any of the polymorphisms was found between proteinuric (n = 45) and non-proteinur-ic (n = 51) patients. Moreover, MTHFR polymorphism does not affect the association between FV Leiden and preeclampsia. In conclusion, FV Leiden mutation and MTHFR TT genotype are associated with the occurrence of preeclampsia, suggesting that, during pregnancy, women carrying these gene variants are prone to develop such a complication.

Download Full-text

Association of factor V Leiden G1691A and prothrombin gene G20210A mutations with adverse pregnancy outcomes

Journal of the Pakistan Medical Association ◽

10.47391/jpma.1377 ◽

2021 ◽

pp. 1-15

Author(s):

Sidra Asad Ali ◽

Bushra Moiz ◽

Lumaan Sheikh

Keyword(s):

Gene Mutation ◽

Pregnancy Outcomes ◽

Pregnancy Loss ◽

Recurrent Pregnancy Loss ◽

Factor V Leiden ◽

Control Group ◽

Factor V ◽

Prothrombin Gene Mutation ◽

Prothrombin Gene ◽

Adverse Pregnancy

Abstract Objective: To determine the association of Factor V Leiden / prothrombin gene mutation in Pakistani women with adverse pregnancy outcomes. Method: The prospective study was conducted at the Aga Khan University Hospital, Karachi, from January 1 to December 31, 2016, and comprised females ?40 years having history of two or more foetal losses with no apparent aetiology. Restriction fragment length polymorphism- Polymerase chain reaction was performed using MnlI and HindIII restriction enzymes for factor V Leiden G1691A and prothrombin gene mutation G20210A. Females with two or more consecutive normal pregnancies were enrolled as the control group. Data was analysed using SPSS 19. Results: Of the 172 participants with a mean age of 29.3±5.9 years (range: 19-38 years). 86(50%) each were healthy controls and those with recurrent pregnancy loss. There were 238 livebirths among the controls compared to 13 in the other group. Factor V Leiden G1691A was identified in 2(2.3%) women, and prothrombin gene mutation G20210A in 1(1.2%) woman in the patient group, while no mutation was identified in the control group. Conclusion: The prevalence of Factor V Leiden / prothrombin gene mutation in women with recurrent pregnancy loss was found to be very low. Continuous....

Download Full-text